Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 4/20 | 0.32 |
| ▸ | CA1 | P00915 | 4/20 | 0.32 |
| ▸ | CA2 | P00918 | 4/20 | 0.32 |
| ▸ | CA7 | P43166 | 4/20 | 0.32 |
| ▸ | CA9 | Q16790 | 4/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10159622 | 0.79 | TSHR (0.34) | LMNATSHRALDH1A1HSD17B10CA12 | |
| SCHEMBL9335201 | 0.77 | LMNA (0.31) | LMNATSHRALDH1A1 | |
| SCHEMBL1323323 | 0.75 | — | — | |
| SCHEMBL8890220 | 0.75 | SETD7 (0.30) | LMNATSHRSETD7ALDH1A1 | |
| SCHEMBL7434231 | 0.74 | — | — | |
| SCHEMBL23279760 | 0.71 | — | — | |
| SCHEMBL48012 | 0.71 | LMNA (0.37) | LMNATSHRALDH1A1CHRM2CHRM4 | |
| SCHEMBL11087986 | 0.70 | HSP90AA1 (0.37) | LMNAALDH1A1TDP1NPSR1 | |
| SCHEMBL30507873 | 0.70 | SLC6A3 (0.32) | LMNATSHRCHRM2CHRM4CHRM5 | |
| SCHEMBL16810704 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117420296-A | Application of CTAB-Au NCs in antibacterial and/or enzymatic chemiluminescence analysis and substrate solution | 上海太阳生物技术有限公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-114544947-A | Reagent kit for detecting SARS-CoV-2 antigen, method and use thereof | 深圳迈瑞生物医疗电子股份有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-113238046-A | Kit for detecting coronavirus antibody and detection method of coronavirus antibody | 深圳迈瑞生物医疗电子股份有限公司 | 2021-08-10 | — | — | CN | disclosed |
| CN-113219171-A | Kit for detecting coronavirus neutralizing antibody and detection method of coronavirus neutralizing antibody | 深圳迈瑞生物医疗电子股份有限公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-112014577-A | Kit for improving detection sensitivity of GPC3 and preparation method thereof | 武汉生之源生物科技股份有限公司 | 2020-12-01 | — | — | CN | disclosed |
| CN-111781385-A | NT-proBNP detection kit and preparation method thereof | 武汉生之源生物科技股份有限公司 | 2020-10-16 | — | — | CN | disclosed |
| US-20090081696-A1 | LUMINESCENCE ENHANCER AND USE THEREOF | FUJIREBIO INC. (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-2028250-A1 | LUMINESCENCE ENHANCER | FUJIREBIO INC. (JP) | 2009-02-25 | — | — | EP | disclosed |
| US-20060199835-A1 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS, INC. (CA) | 2006-09-07 | — | — | US | disclosed |
| WO-2005014584-A9 | 3-(INDOL-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES,3-(BENZIMIDAZOL-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES, AND 3-(INDOLIN-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES; THEIR PREPARATION AND USE AS MODULATORS OF APOPTOSIS | AEGERA THERAPEUTICS INC (CA) | 2005-06-23 | — | — | WO | disclosed |
| US-6287767-B1 | FORMING ENZYME COMPLEX BY BINDING ENZYME TO SUBSTANCE; ADDING HYDROPHOBIC FLUORESCENT EMITTER AND 1,2-DIOXITANE COMPOUND; ALLOWING ENZYME TO CLEAVE DIOXITANE COMPOUND; SEGREGATING EMITTER AND OXYANION TO CAUSE FLUORESCENCE | TROPIX, INC. | 2001-09-11 | — | — | US | disclosed |
| US-5753436-A | Chemiluminescent energy transfer assays | TROPIX, INC. (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0450652-B1 | Liquid crystalline polyesters and methods for their production | MITSUBISHI CHEM CORP (JP) | 1997-12-17 | — | — | EP | disclosed |
| US-5340911-A | High impact and tensile strength | MITSUBISHI KASEI CORPORATION (JP) | 1994-08-23 | — | — | US | disclosed |
| US-5310859-A | Terephthalic acid, hydroxybenzoic acid, ethylene glycol | MITSUBISHI KASEI CORPORATION (JP) | 1994-05-10 | — | — | US | disclosed |
| EP-0450652-A2 | Liquid crystalline polyesters and methods for their production | Mitsubishi Chemical Corporation (JP) | 1991-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199835-A1 | Neuroprotective and anti-proliferative compounds | MKI67, NES, BCL2A1 | LMNA 864/4885TSHR 1896/4885SETD7 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.